ClinicalTrials.gg
CompletedNCT03795389Updated Sep 13, 2021

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

A Phase 1 interventional study of DM199 in Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate) and Chronic Kidney Disease, Stage 4 (Severe), sponsored by DiaMedica Therapeutics Inc. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-13.

Sponsored by DiaMedica Therapeutics Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
559th of 819
33 · median 72
Started
2019
with 52 others
Phase 1
93 of 988
15 open now
Registered
575th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 559th largest by enrollment of the 819 interventional ones that give a count, is one of 53 that started in 2019, is one of 93 in phase 1, and was the 575th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

An open-label, phase IB, multi-center study evaluating DM199 in subjects with Type 1 Diabetes or Type 2 Diabetes and Stage 3 or 4 Chronic Kidney Disease. The primary objectives of this study are to evaluate safety, tolerability, and PK profile of DM199 in these subjects.

Read the detailed description

The study evaluates the safety, tolerability, and PK profile of DM199 in subjects with T1D or T2D and with Stage 3 or Stage 4 CKD. Additionally, this study evaluates urine concentrations of KLK1 pre and post dose.

Cohort 1: Subjects with T1D or T2D and Stage 3 CKD will be administered one of three DM199 doses: 3.0 ug/kg or 5.0 ug/kg or 8.0 ug/kg single SC dose. Cohort 2: Subjects with T1D or T2D and Stage 4 CKD will be administered a single 3.0 µg/kg single SC dose. Secondary and exploratory study objectives include collection and analysis of vital signs, biomarkers, eGFR, blood glucose, and ECG's.

03

Conditions studied

  • Chronic Kidney Disease
  • Chronic Kidney Disease, Stage 3 (Moderate)
  • Chronic Kidney Disease, Stage 4 (Severe)
  • Diabetes

Keywords

  • Diabetes
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is willing and able to provide for study participation.
  • Subject is ≥ 18 years of age.
  • Subject has an established diagnosis of T1D or T2D as determined by medical evaluation at screen.
  • Subjects A1c \<9.8%
  • Subject is clinically stable with respect to underlying renal impairment and diabetes, as assessed by the Investigator's medical evaluation.
  • Subject has been diagnosed with Stage 3 CKD as defined by (MDRD) between 30 - \<60 or Stage 4 as defined by eGFR \<30 (not on dialysis) at screening.
  • Subject has a (BMI) between 18 to 45 kg/m2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Subject has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 0.
  • Subject is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.
  • Subject has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis.
  • Subject has had any ≤ 3 months prior to enrollment or will require vaccination during the study.
  • Subject must not be taking an ACEi medication for 5 half-lives prior to study drug administration and for 5 days post study drug administration.
  • Subject is unwilling or unable to limit smoking to ≤ 10 cigarettes per day (or other products that contain nicotine limited to \< 200 mg of nicotine/day) during the study participation period.
  • Subject has a current or active malignancy ≤ 3 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ six months have elapsed since the procedure.
  • Subject has an active infection at the time of enrollment, and/or a history of acute bacterial, viral, or fungal systemic infections that required systemic treatment in the last four weeks prior to enrollment.
  • Subject has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).
  • Subject has serological evidence of (HIV), surface antigen (HBsAg), or anti- virus (Anti-HCV) at screen.
  • Subject is pregnant or nursing or is planning a pregnancy during the study period.
  • Subject is male or female of , is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective during the study.
  • Subject has received any drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration on Day 1
  • Subject has renal artery stenosis as determine at screen with medical history.
  • Subject has hypotension as defined by systolic blood pressure ≤ 90 and diastolic blood pressure ≤ 60 mmHg.
  • Subject has Proteinuria: PCR>2000mg/gm (spot testing).
  • Subject does not have adequate venous access for blood sampling.
  • Subject has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results.
  • Subject has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
  • Subject has any of the following conditions as determined by or medical record:

    • Any significant arrhythmia or conduction abnormality, which, in the opinion of the Investigators and Medical Monitor, may interfere with the safety of the subject.
  • Subject is taking Cimetidine, St. John's Wort, or any other herbal or probiotic supplement.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    3.0 µg/kg SC, single dose

    n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).

    Drug: DM199

  • Experimental
    5.0 µg/kg SC, single dose

    n=8, study group of T1D or T2D with stage 3 CKD.

    Drug: DM199

  • Experimental
    8.0 µg/kg SC, single dose

    n=8, study group of T1D or T2D with stage 3 CKD.

    Drug: DM199

Interventions

06

What researchers measure

Primary outcomes

  1. Safety as assessed by incidence, severity, and causality of adverse events

    Time frame: 11 days

  2. Tolerability as assessed by incidence and severity of AEs

    Time frame: 11 days

  3. plasma measurements of DM199

    as measured in the three different dosing groups; 3.0 ug/kg, 5.0 ug/kg, and 8.0 ug/kg.

    Time frame: 11 days

  4. DM199 urine concentrations of KLK1

    urine KLK1 will be measured pre and post study drug administration.

    Time frame: 11 days

Secondary outcomes

  1. C Reactive protein (CRP)

    Time frame: 11 days

  2. Matrix Metalloproteinase-9 (MMP-9)

    Time frame: 11 days

  3. Vascular Endothelial Growth Factor (VEGF)

    Time frame: 11 days

  4. Nitric Oxide (NO)

    Time frame: 11 days

  5. Serum creatinine

    Time frame: 11 days

  6. Cystatin C

    Time frame: 11 days

  7. neutrophil gelatinase-associated prostaglandin E2

    Time frame: 11 days

  8. Urine Kidney Injury Molecule-1 (Kim1)

    Time frame: 11 days

Other outcomes

  1. serum creatinine

    Time frame: 11 days

  2. Blood glucose

    Time frame: 11 days

07

Study locations

3 sites
  • Clinical Pharmacology of Miami
    Hialeah, Florida 33014, United States
  • Orlando Clinical Research Center Inc
    Orlando, Florida 32803, United States
  • Prism Research
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jul 2019, 5 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2019
First posted
Jan 7, 2019
StartActual
Feb 12, 2019
Primary completionActual
Jul 21, 2019
CompletionActual
Jul 21, 2019
Last update
Sep 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03795389
Lead sponsor
DiaMedica Therapeutics Inc
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Feb 12, 2019
Primary completion
Jul 21, 2019
Completion
Jul 21, 2019
Last update
Sep 13, 2021

Study contacts

Harry Alcorn, Pharm.D.
study director · DiaMedica Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM199

Start the discussion